What is LCTX's market cap?

$260.49M, based on the Nov 4 close of $1.03.

Does Lineage Cell Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of LCTX is sold short?

25.9M shares, 12.9% of float, as of Oct 15, 2026.

What sector is LCTX in?

Healthcare, in the Biotechnology industry.

NYSE American · LCTXHealthcareBiotechnology

Lineage Cell Therapeutics, Inc. (LCTX)

$1.03+1.98%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$1.01▼ 48.47% in range

Nov 3, 2025Low $0.90 · High $1.96Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Lineage Cell Therapeutics closed at $1.03 on Nov 4, up 1.98%, 47.4% below its 52-week closing high. Volume of 959.0K shares was 0.68× its 20-day average (below normal).

Split-adjusted performance: +9.8% over one month, -28.0% over six months, -47.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.07M, down 61.3% from a year earlier, with a net margin of 138.6%.

Short interest was 25.9M shares at the Oct 15 settlement, down 10.9% from the prior report (12.9% of float, 16.8 days to cover).

Market cap$260.5M252.9M shares

Revenue · quarter$1.1M−61.3% YoY

Diluted EPS$-0.03—

P/E · TTM—P/S 19.9×

Net margin138.6%Gross 100.0%

Dividend yieldNone

52-week range0.90 – 1.96−47.4% from high

Volume959.0K0.68× 20-day avg

Volatility · 60d52.5%Annualised

Short % of float12.9%16.8 days to cover

Net cash$50.8MCash $50.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.0%1M +9.8%3M −8.8%6M −28.0%YTD −38.3%1Y −47.4%3Y −8.8%5Y −55.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum45

Revenue growth18

Net margin97

Value (low P/E)—

Size51

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short25.9M−10.9% vs prior

Days to cover16.8Settled Oct 15

% of float12.9%

Short vol. 10d66.9%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
LCTXLineage Cell Therapeutics	$1.03	+1.98%	−28.0%	−61.3%	138.6%	—	$260.5M
LXEOLexeo Therapeutics	$3.23	+3.86%	−48.2%	—	—	—	$265.1M	Compare
ALECAlector	$2.28	+11.22%	−11.3%	−57.8%	−692.5%	—	$254.6M	Compare
FATEFate Therapeutics	$2.09	+2.45%	−8.7%	+9.2%	−1448.6%	—	$250.4M	Compare
CABACabaletta Bio	$1.42	0.00%	−61.9%	—	—	—	$240.8M	Compare
SABSSAB Biotherapeutics	$3.18	+1.92%	−16.3%	—	—	—	$289.3M	Compare
PROKProKidney	$1.12	+4.67%	−42.9%	−32.1%	−18948.0%	—	$234.1M	Compare
OCGNOcugen	$0.8745	+17.35%	−39.9%	+8.4%	−1671.8%	—	$296.6M	Compare
IPSCCentury Therapeutics	$1.67	+9.87%	−28.6%	—	—	—	$302.4M	Compare

News about Lineage Cell Therapeutics

All news →

No recent articles focused on Lineage Cell Therapeutics. 3 articles mention it in passing.

Quick answers

What does Lineage Cell Therapeutics do?: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON.
What is LCTX's market cap?: $260.49M, based on the Nov 4 close of $1.03.
Does Lineage Cell Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of LCTX is sold short?: 25.9M shares, 12.9% of float, as of Oct 15, 2026.
What sector is LCTX in?: Healthcare, in the Biotechnology industry.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

HQ: Carlsbad, CA77 employeesListed Mar 5, 1992lineagecell.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology